FDX1 and glioblastoma: Moreover, we conducted a screening of numerous small molecule compounds exhibiting high FDX1 expression, which demonstrated varying levels of sensitivity and resistance among glioblastoma multiforme (GBM) patients. Notably, GBM patients classified within the high-risk group exhibited pronounced resistance to ACY-1215, Panobinostat, SB505124, and Trichostatin A, while displaying heightened sensitivity to Temozolomide, PLX-4720, Dactolisib, and Cisplatin.